SWOG and WIN Join Forces to Advance Precision Oncology

Posted: Tuesday, December 09, 2025

December 9, 2025

SWOG Cancer Research Network has joined the WIN Consortium in Precision Oncology, allying two organizations with deeply aligned missions to accelerate progress against cancer.

The WIN Consortium offers a global platform for innovation, collaboration, and impact in precision oncology. Its mission is to significantly improve survival for cancer patients worldwide through international cooperation, cutting-edge clinical studies, and educational initiatives such as the renowned WIN Symposium series.

SWOG is one of the five network groups that make up the National Cancer Institute’s National Clinical Trials Network (NCTN), designing and conducting NCI-sponsored cancer clinical trials for adults. Its mission is to improve lives through cancer trials and translational research. In addition, SWOG supports non-federal studies through the Hope Foundation–based SWOG Clinical Trials Partnerships and its Preferred Partnerships Program.

“After over ten years of working closely with both SWOG and the WIN Consortium, I know how powerful their shared commitment to innovation can be. By joining forces, we are building a truly patient-centered engine for accelerating breakthroughs in precision oncology,” said Dr. Razelle Kurzrock, Chief Medical Officer of WIN; Professor of Medicine, Director, Center for Precision Oncology and Rare Cancers, MCW Cancer Center; and Chair, Early Therapeutics and Rare Cancers
Committee, SWOG.

By joining the WIN Consortium, SWOG will collaborate with WIN and its member institutions to advance precision medicine and biomarker-driven research. The partnership aims to support initiatives that have the potential to reduce the cost of cancer care while improving its clinical effectiveness—ultimately benefiting patients across the globe.

View the press release here: Download pdf